These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 11264457)

  • 41. Schizophrenia: moving beyond monoamine antagonists.
    Conn PJ; Tamminga C; Schoepp DD; Lindsley C
    Mol Interv; 2008 Apr; 8(2):99-107. PubMed ID: 18403654
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Schizophrenia: diverse approaches to a complex disease.
    Sawa A; Snyder SH
    Science; 2002 Apr; 296(5568):692-5. PubMed ID: 11976442
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brain glycogen and its role in supporting glutamate and GABA homeostasis in a type 2 diabetes rat model.
    Sickmann HM; Waagepetersen HS; Schousboe A; Benie AJ; Bouman SD
    Neurochem Int; 2012 Feb; 60(3):267-75. PubMed ID: 22244844
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of cortical inhibition in the pathophysiology and treatment of schizophrenia.
    Daskalakis ZJ; Fitzgerald PB; Christensen BK
    Brain Res Rev; 2007 Dec; 56(2):427-42. PubMed ID: 17980435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pathophysiology of schizophrenia and its impact on pharmacotherapy].
    Widschwendter CG; Fleischhacker WW
    Fortschr Neurol Psychiatr; 2005 Nov; 73 Suppl 1():S32-7. PubMed ID: 16270242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The neuronal pathology of schizophrenia: molecules and mechanisms.
    Reynolds GP; Harte MK
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):433-6. PubMed ID: 17371293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monoaminergic synapses and schizophrenia: 45 years of neuroleptics.
    Bennett MR
    J Psychopharmacol; 1998; 12(3):289-304. PubMed ID: 10958257
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct receptor cross-talk can mediate the modulation of excitatory and inhibitory neurotransmission by dopamine.
    Lee FJ; Wang YT; Liu F
    J Mol Neurosci; 2005; 26(2-3):245-52. PubMed ID: 16012198
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Biochemistry of schizophrenia and mechanism of action of neuroleptics].
    Loo H; Cuche H; Sechter D
    Sem Hop; 1982 Dec; 58(44):2565-72. PubMed ID: 6130604
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cellular and molecular neuropathology of schizophrenia: new directions from developmental neurobiology.
    Turner EE; Fedtsova N; Jeste DV
    Schizophr Res; 1997 Oct; 27(2-3):169-80. PubMed ID: 9416646
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Possible mechanisms of neurodegeneration in schizophrenia.
    Pérez-Neri I; Ramírez-Bermúdez J; Montes S; Ríos C
    Neurochem Res; 2006 Oct; 31(10):1279-94. PubMed ID: 17006758
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
    Gaspar PA; Bustamante ML; Silva H; Aboitiz F
    J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A two-process theory of schizophrenia: evidence from studies in post-mortem brain.
    Deakin JF; Simpson MD
    J Psychiatr Res; 1997; 31(2):277-95. PubMed ID: 9278190
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.
    de Bartolomeis A; Iasevoli F; Tomasetti C; Buonaguro EF
    Mol Neurobiol; 2015 Dec; 52(3):1771-1790. PubMed ID: 25394379
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways.
    Perez SM; Lodge DJ
    Drug Des Devel Ther; 2014; 8():887-96. PubMed ID: 25061280
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.
    McCullumsmith RE; Hammond J; Funk A; Meador-Woodruff JH
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1535-42. PubMed ID: 22283761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glutamate and dopamine in schizophrenia: an update for the 21st century.
    Howes O; McCutcheon R; Stone J
    J Psychopharmacol; 2015 Feb; 29(2):97-115. PubMed ID: 25586400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia.
    Kim YK; Choi J; Park SC
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28358303
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epilepsy, schizophrenia, and the extended amygdala.
    Stevens JR
    Ann N Y Acad Sci; 1999 Jun; 877():548-61. PubMed ID: 10415670
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis.
    Yang AC; Tsai SJ
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28771182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.